Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments for diseases involving the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Product Development - Initial development of the technology is targeted at treating pain, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology serves as a platform that could potentially address various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Upcoming Events - Brad Hauser, President and CEO of Autonomix, will present at LSI USA '26 on March 17, 2026, at 9:15 AM PT [1] - Management will also be available for in-person one-on-one meetings with registered investors during the conference [2] - LSI USA '26 is a prominent global medtech summit that brings together executives, investors, and innovators from the healthcare industry [3]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments for diseases involving the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [4] Product Development - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is associated with severe pain and lacks reliable treatment options [5] - The technology serves as a platform for addressing multiple indications, including cardiology, hypertension, and chronic pain management across a wide disease spectrum [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Upcoming Events - Brad Hauser, President and CEO of Autonomix, will present at LSI USA '26 on March 17, 2026, at 9:15 AM PT [1] - Management will also be available for in-person one-on-one meetings with registered investors during the conference [2] - LSI USA '26 is a prominent global medtech summit that brings together executives, investors, and innovators from the healthcare industry [3]

Core Insights - Autonomix Medical, Inc. has been selected for an oral presentation at the Best Innovation Competition during the Cardiovascular Research Technologies (CRT) 2026 conference, showcasing its innovative technology for nerve-targeted treatments [1][2]. Company Overview - Autonomix is a medical device company focused on developing advanced technologies for diagnosing and treating diseases related to the nervous system. Its first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4]. - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, potentially revolutionizing patient care [4]. Technology and Applications - The initial focus of Autonomix's technology is on treating pain associated with pancreatic cancer, a condition known for causing severe pain and lacking reliable treatment options. The technology is also positioned to address various other indications, including cardiology, hypertension, and chronic pain management [5]. - The investigational technology has not yet received marketing clearance in the United States [5]. Presentation Details - The presentation will be delivered by CEO Brad Hauser on March 9, 2026, emphasizing the scientific innovation and clinical relevance of the company's approach to nerve treatment [2][3]. - The CRT Best Innovation Competition is recognized for highlighting transformative technologies that can significantly impact patient care [2].

Core Insights - Autonomix Medical, Inc. is set to present clinical feasibility and outcome data on a novel radiofrequency (RF) ablation technique for transvascular peripheral nerve neurolysis at the Cardiovascular Research Technologies (CRT) 2026 Meeting [1][2] Group 1: Presentation Details - The abstract titled "Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes" will be presented during the Top Abstract Session on March 7, 2026 [2] - Dr. Nikola Cesarovic will deliver a six-minute presentation focusing on the clinical feasibility and early outcomes of the RF-based approach designed to selectively disrupt peripheral nerve activity [2][3] Group 2: Technology and Applications - Autonomix's technology aims to identify and target specific nerve signals, potentially offering greater therapeutic precision compared to conventional ablation techniques [2][3] - The company is initially developing this technology for pain treatment, particularly for pancreatic cancer, and believes it can address multiple indications across various medical fields, including cardiology and chronic pain management [4][5] Group 3: Company Overview - Autonomix Medical, Inc. is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array [4] - The technology is investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. is focused on advancing precision nerve-targeted treatments and has emphasized the importance of building clinical credibility through rigorous scientific engagement and peer-reviewed publications [1][2]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to revolutionizing the diagnosis and treatment of diseases involving the nervous system. The company’s technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4]. - The company is initially developing its technology for pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options. The technology has the potential to address various indications, including cardiology, hypertension, and chronic pain management [5]. Publication Strategy - The company has focused on expanding its scientific publication and presentation efforts over the past 12 to 18 months. This strategy includes submitting clinical and technical data to competitive, peer-reviewed scientific forums, which is seen as essential for validating the technology and supporting long-term growth [2].

Core Insights - Autonomix Medical, Inc. is set to present new long-term clinical data on its nerve-targeted treatments for chronic pain in pancreatic cancer at the Society of Surgical Oncology (SSO) 2026 Annual Meeting [1][2] Company Overview - Autonomix Medical is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a first-in-class platform system technology that includes a catheter-based microchip sensing array [4] - The company's technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, with initial development targeting pain management in pancreatic cancer [5] Clinical Presentation - Dr. Clarke Wilkirson will present findings titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation," highlighting the potential of Autonomix's minimally invasive approach to improve pain control and quality of life for patients [2][3] - The presentation will consist of a five-minute talk followed by a two-minute Q&A session, emphasizing the significance of the long-term clinical analysis [2] Industry Context - The SSO Annual Meeting serves as a platform for leading surgical oncologists, researchers, and healthcare professionals to discuss advancements in surgical oncology and emerging clinical technologies [3]

Core Insights - Autonomix Medical, Inc. is set to present final clinical data on its transvascular radiofrequency (RF) ablation approach for pain management in pancreatic adenocarcinoma at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases related to the nervous system [5] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The initial application of this technology is aimed at treating pain, particularly in pancreatic cancer, which is known for causing severe pain without reliable treatment options [6] Clinical Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation" has been accepted as an ePoster for the conference [2] - The ePoster will be presented by Dr. Clarke Wilkirson on February 6, 2026, during a dedicated session that includes a 10-minute presentation followed by a 5-minute discussion [3] Industry Context - The SIO Annual Scientific Meeting gathers leading clinicians, researchers, and innovators focused on advancing minimally invasive, image-guided therapies for cancer care [4] - The presentation at this conference highlights the potential of Autonomix's RF ablation approach to address significant unmet clinical needs in pain management for pancreatic cancer patients [4]

Core Insights - Autonomix Medical, Inc. has presented new clinical data showing significant pain relief in pancreatic cancer patients across all disease stages, emphasizing the effectiveness of their nerve-targeted treatment approach [1][2][4]. Group 1: Clinical Findings - The post hoc subgroup analysis from the ongoing Proof-of-Concept study indicates consistent pain reduction in pancreatic cancer patients treated with a transvascular RF denervation platform, regardless of disease severity [2]. - Rapid onset of pain relief was observed, with patients showing marked reduction in average pain within 24 hours post-procedure [6]. - At 7 days post-procedure, 93.75% of responding patients improved from severe pain to mild or moderate pain, with some achieving near-elimination of pain [6]. - Sustained benefits were noted, with approximately two-thirds of responding patients maintaining mild or eliminated pain levels at 4-6 weeks post-procedure [6]. - At 3 months post-procedure, no responding patients reported severe pain, and 50% maintained mild or eliminated pain levels [6]. - Notably, even late-stage (Stage 4) cancer patients experienced meaningful pain relief, transitioning from severe to mild or moderate pain [6]. Group 2: Presentation Details - The findings were presented at the 2026 ASCO Gastrointestinal Cancers Symposium, under the poster titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" [4][5]. - The presentation was made by Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc., during Poster Session B [5]. Group 3: Company Overview - Autonomix Medical, Inc. focuses on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform system technology that includes a catheter-based microchip sensing array [6][8]. - The company is initially developing its technology for pain treatment, particularly targeting pancreatic cancer, which is known for causing debilitating pain and lacking reliable solutions [8].

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 100 points, down 0.22% to 48,353.51, NASDAQ slipping 0.16% to 23,436.70, and S&P 500 dropping 0.13% to 6,896.56 [1] - Energy shares rose by 0.6%, while consumer discretionary stocks fell by 0.3% [1] Commodity Prices - Oil prices increased by 0.5% to $58.34, gold rose by 0.9% to $4,383.10, silver surged 7.2% to $75.515, and copper climbed 2.6% to $5.7105 [5] European Market Performance - European shares showed positive movement, with the eurozone's STOXX 600 gaining 0.53%, Spain's IBEX 35 Index rising 0.85%, London's FTSE 100 up 0.70%, Germany's DAX 40 increasing by 0.57%, and France's CAC 40 rising 0.63% [6] Asian Market Performance - Asian markets closed mostly lower, with Japan's Nikkei 225 down 0.37%, Hong Kong's Hang Seng Index up 0.86%, China's Shanghai Composite slightly down by 0.004%, and India's BSE Sensex falling 0.02% [7] Company-Specific Movements - FONAR Corporation shares surged 28% to $18.82 following confirmation of a take-private deal [8] - Autonomix Medical, Inc. shares increased by 30% to $0.6943 after receiving a patent grant [8] - Cemtrex, Inc. shares rose 40% to $2.9500 as the company returned to profitability [8] - Flushing Financial Corporation shares dropped 8% to $15.46 amid a merger announcement and strategic investment [8] - New Era Energy & Digital, Inc. shares fell 23% to $2.07 following a lawsuit response [8] - OceanFirst Financial Corp. shares decreased by 6% to $18.42 after announcing an acquisition plan for Flushing [8] Economic Indicators - The Case-Shiller Home Price Index increased by 1.3% year-over-year in October, slightly down from a 1.4% increase in the previous month and above market estimates of 1.1% [10] - The FHFA house price index rose 0.4% in October, following a 0.1% decline in September, and compared to market estimates of a 0.1% increase [10] - The Chicago Business Barometer surged to 43.5 in December from 36.3 in the previous month, exceeding market expectations of 39.5 [10]

Core Insights - Autonomix Medical, Inc. has been granted a new European patent (EP4230133) that enhances its strategic position in the nerve-sensing and modulation market, which is valued in the multi-billion-dollar range [1][2] - The patent covers systems and methods for precise treatment of cardiac tissues, including feedback-driven neuromodulation and denervation, which could transform treatment in cardiology and related fields [1][2] Company Overview - Autonomix is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, with a first-in-class platform that includes a catheter-based microchip sensing array [4] - The company aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, which could significantly improve patient outcomes [4] Technology and Applications - The newly granted patent expands the company's ability to provide precision nerve-targeted therapies for conditions such as hypertension, arrhythmia management, heart failure, and refractory angina [2][3] - Autonomix's technology platform has the potential to address multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [3][5] Market Potential - The patent positions Autonomix to capitalize on high-growth areas in cardiology, potentially reducing complications associated with traditional systemic treatments [2] - The company is initially developing its technology for pain management, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [5]